🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. CP101

    Finch Therapeutics Group

    Recurrent C. Difficile Infection

    phase 3 mab terminated

    1 trial

  2. CPT Dermatophagoides pteronyssinus LETI 100 HEP/ml, Formodual 100/6 microgramos/pulsación Solución para inhalación en envase a presión, Montelukast Teva 10 mg comprimidos recubiertos con película EFG, Budesonida Aldo-Unión- 200 microgramos/pulsación suspensión para inhalación en envase a presión., Salbutamol Aldo-Unión 100 microgramos/dosis suspensión para inhalación en envase a presión, AVAMYS 27.5 micrograms/spray, nasal spray suspension, Formodual Nexthaler 200 microgramos/6 microgramos por inhalación po

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis to Dermatophagoides pteronyssinus and Dermatophagoides farinae

    phase 3 small molecule active

    1 trial

  3. CT-P55, Cosentyx 150 mg solution for injection in pre-filled syringe

    Celltrion Healthcare Australia Pty Ltd

    Plaque psoriasis

    phase 3 small molecule active

    1 trial

  4. CYCLOPHOSPHAMIDE, EPIRUBICIN, TRASTUZUMAB EMTANSINE, PACLITAXEL, DOXORUBICIN, DOCETAXEL, PACLITAXEL ALBUMIN-BOUND, TRASTUZUMAB, CARBOPLATIN, Phesgo 1200 mg/600 mg solution for injection, Phesgo 600 mg/600 mg solution for injection, TRASTUZUMAB, PERTUZUMAB

    The George Institute

    HER2-positive early breast cancer

    phase 3 small molecule active

    1 trial

  5. CYTARABINE, CYTARABINE, Liposomal Annamycin, 0.9% Sodium Chloride Injection, USP/Ph. Eur./BP/JP

    Moleculin Biotech

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  6. Cablivi 10 mg powder and solvent for solution for injection, Cablivi 10 mg powder and solvent for solution for injection, Cablivi 10 mg powder and solvent for solution for injection

    Sanofi-aventis Healthcare Pty Ltd

    Thrombotic Thrombocytopenic Purpura

    phase 3 small molecule active

    1 trial

  7. Calcium carbonate

    Arrowhead Pharmaceuticals Ireland Limited

    Uterine Contraction

    phase 3 small molecule completed

    1 trial

  8. Calquence 100 mg hard capsules, CYCLOPHOSPHAMIDE, RITUXIMAB, DOXORUBICIN, Placebo, 100mg hard capsules; Identical to IMP apart from the active substance, VINCRISTINE, PREDNISONE

    Lacuna Pharma Pty Ltd

    Diffuse large B-cell lymphoma

    phase 3 small molecule active

    1 trial

  9. Capecitabine Accord 150 mg film-coated tablets, Fluorouracil 25 mg/ml Solution for Injection or Infusion, Irinotecan Accord 20 mg/ml Solution à diluer pour perfusion, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion

    Ningbo Cancer Hospital

    Stage III colorectal cancer

    phase 3 small molecule active

    1 trial

  10. Capivasertib, Faslodex 250 mg solution for injection., Placebo to Capivasertib, Capivasertib

    AstraZeneca AB

    Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer

    phase 3 small molecule active

    1 trial

  11. CardiolRx™ Placebo is a non-aqueous solution of medium chain triglycerides with 1.0% vitamin E as anti-oxidant. CardiolRx™ Placebo is a pale yellow clear liquid. The CardiolRx™ Placebo product is essentially the same as the CardiolRx™ drug product with the exception that the placebo does not include the active drug substance, cannabidiol., CardiolRx

    Cardiol Therapeutics

    Recurrent Pericarditis

    phase 3 small molecule active

    1 trial

  12. Carraguard (PC-515)

    United Therapeutics Europe Ltd

    HIV Infections

    phase 3 small molecule completed

    2 trials

  13. Ceftazidime - Avibactam ( CAZ-AVI)

    Pfizer

    Complicated Urinary Tract Infection

    phase 3 small molecule completed

    1 trial

  14. Ceftazidime-avibactam

    Pfizer

    Complicated Intra-abdominal Infection

    phase 3 small molecule completed

    1 trial

  15. Cellulose Sulfate gel (6%)

    United Therapeutics Europe Ltd

    HIV Infection

    phase 3 small molecule terminated

    1 trial

  16. Cervarix™

    GlaxoSmithKline

    Infections, Papillomavirus

    phase 3 mab completed

    1 trial

  17. Cholecalciferol

    United Therapeutics Europe Ltd

    Chronic Obstructive Pulmonary Disease

    phase 3 other completed

    1 trial

  18. Cholecalciferol (Vitamin D/Vigantol oil)

    United Therapeutics Europe Ltd

    Respiratory Tract Infections

    phase 3 other completed

    1 trial

  19. Choline Chloride for Injection

    Protara Therapeutics

    Choline Deficiency

    phase 3 small molecule active

    1 trial

  20. Cimzia 200 mg solution for injection in pre-filled syringe, SODIUM CHLORIDE

    Pari Pharma GmbH

    Adult women with recurrent implantation failures (RIF)

    phase 3 small molecule active

    1 trial

  21. Cinryze®

    Takeda

    Acute Antibody-Mediated Rejection (AMR)

    phase 3 mab terminated

    1 trial

  22. Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Capecitabine Accord 500 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., The Placebo is formulated as 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0., Fluorouracil Injection, 50 mg/ml, solution for injection, Mycophenolate Mofetil Accord 250 mg capsules, Capecitabine Accord 150 mg film-coated tablets

    AstraZeneca AB

    Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  23. Clazakizumab

    CSL Behring GmbH

    Antibody-mediated Rejection

    phase 3 mab terminated

    1 trial

  24. Clesrovimab

    Merck KGaA, Darmstadt, Germany

    Respiratory Syncytial Virus Infection

    phase 3 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources